Sai Life Sciences (NSE:SAILIFE, BOM:544306) has begun commercial operations of the second phase of the production block with 91 kiloliter of capacity at its Bidar facility in Karnataka, India.
This is the second and final phase of the unit's overall capacity addition of 195 kiloliter, according to a Friday filing to the Indian stock exchanges.
With this, the combined capacity of Unit IV Bidar facility will be 640 kiloliter, which will supply to registered starting materials (RSM), intermediates, and active pharmaceutical ingredients (APIs) for clinical and commercial purposes.
The company's shares were up nearly 1% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。